Enhancing Cardiovascular Risk Prediction in Type 2 Diabetes: The Role of NT-proBNP as a Prognostic Biomarker

Cardiovascular complications in type 2 diabetes remain a significant clinical challenge, with existing risk prediction approaches potentially missing important prognostic information. N-terminal pro-B-type natriuretic peptide (NT-proBNP), a biomarker reflecting cardiac stress and dysfunction, may offer valuable insights for enhanced risk stratification in this population. This systematic review examined the available evidence regarding the role of NT-proBNP in cardiovascular risk prediction among patients with type 2 diabetes. Following comprehensive literature searches across multiple databases and systematic screening processes, four studies involving over 8,000 participants were identified for qualitative synthesis. Across all studies, elevated NT-proBNP levels demonstrated consistent associations with increased cardiovascular risk. The biomarker exhibited strong discriminative capabilities for various cardiovascular endpoints, with performance metrics suggesting utility comparable to complex multivariable clinical models when used independently. When incorporated alongside traditional risk factors, NT-proBNP consistently enhanced predictive performance across studies. Cross-sectional investigations revealed a notable prevalence of subclinical cardiac dysfunction among asymptomatic diabetes patients, indicating potential opportunities for early identification and intervention. However, several important limitations constrain the current evidence base, including the small number of available studies, heterogeneity in methodological approaches, variation in biomarker thresholds, and absence of data demonstrating clinical benefit from biomarker-guided care strategies. Despite these constraints, NT-proBNP appears to hold promise as a valuable adjunct for cardiovascular risk assessment in type 2 diabetes populations. The ability of this marker to identify subclinical dysfunction and predict adverse outcomes beyond conventional clinical variables addresses important gaps in current risk stratification approaches. Nevertheless, the limited evidence necessitates further investigation through large-scale prospective studies and randomized controlled trials to establish standardized diagnostic thresholds, validate predictive performance across diverse populations, and demonstrate that biomarker-enhanced risk assessment translates into meaningful improvements in clinical outcomes and healthcare delivery.